Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00687219
Recruitment Status : Completed
First Posted : May 30, 2008
Results First Posted : December 2, 2011
Last Update Posted : April 7, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C compensated liver cirrhosis. Participants who are hepatitis C virus ribonucleic acid (HCV-RNA) positive after 24 weeks of treatment will be discontinued from therapy.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Liver Cirrhosis Biological: Peginterferon alfa-2b Drug: Ribavirin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 102 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin
Study Start Date : June 2007
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Peginterferon alfa-2b + Ribavirin Biological: Peginterferon alfa-2b
Administered at 1.0 µg/kg/week SC for 48 weeks
Other Name: SCH 054031

Drug: Ribavirin
Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
Other Name: SCH 018908

Primary Outcome Measures :
  1. Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response) [ Time Frame: Measured at 24 weeks after 48 weeks treatment (72 weeks) ]
    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

Secondary Outcome Measures :
  1. Number of Participants With Undetectable HCV-RNA at Week 24 [ Time Frame: Week 24 ]
    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

  2. Number of Participants With Undetectable HCV-RNA at End of Treatment [ Time Frame: Up to 48 weeks ]
    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults aged 20-70 years.
  • Positive quantitative serum HCV-RNA.
  • Participants classified as A in Child-Pugh classification, and who do not have ascites or hepatic encephalopathy.
  • Diagnosed with type C compensated liver cirrhosis based on liver biopsy performed within 3 years or latest celioscopy.
  • Prolonged prothrombin time by <=3.0 sec.
  • Participants and partners of participants willing to use adequate contraception during the course of the study.
  • Participants who can be hospitalized for at least 14 days since treatment initiation.
  • Weight >40 kg and <=100 kg
  • Hematology laboratory results of:

    • hemoglobin >=12 g/dL
    • neutrophil count >=1,500/mm^3
    • platelet count >=70,000/ mm^3
  • Blood chemistry results of:

    • albumin and direct bilirubin within normal limits
    • alpha fetoprotein (AFP) within reference range
    • AFP-L3<=10%
    • Protein induced by vitamin K (PIVKA)-II <=100 mAU/mL

Exclusion Criteria:

  • Participants who did not previously respond virologically to combination therapy with interferon (including polyethylene glycol-modified interferon) and ribavirin
  • Participants who had previously received treatment with interferon for whom at least 90 days have not elapsed since the end of previous treatment
  • Participants who have received treatment within 14 days prior to registration with injectable preparations containing glycyrrhizin/cysteine/glycyron or shosaikoto
  • Participants who have received administration of drugs having antiviral, anti-tumor, or immuno-modulating effect (including glucocorticoids and radiation therapy) within 90 days prior to registration (excluding local administration and topicals)
  • Participants who have received other investigational drugs within 180 days prior to registration
  • Hepatitis B surface (HBs) antigen positive
  • Antinuclear antibody >=320 times
  • Serum creatinine exceeding the upper limit of reference range
  • Participants with fasting blood glucose >=110 mg/dL (participants with fasting blood glucose >=110 mg/dL and <126 mg/dL can be registered if their hemoglobin A1C (HbA1c) is <6.5%) [fasting blood glucose should be measured when participants are not receiving treatment for diabetes mellitus]
  • Participants with any of the following: diabetes mellitus that requires treatment; thyroid function disorder not controlled by treatment; liver disease such as autoimmune, alcoholic and drug-induced liver diseases; hemophilia; arrhythmia requiring treatment; co-existing hypertension not controlled by drug therapy (systolic blood pressure [BP] >=160mmHg or diastolic BP>=100mmHg); chronic pulmonary disease; hemoglobinopathies (thalassemia, sickle cell anemia); malignant tumors or who have a history of malignant tumor within the past 5 years; organ transplants (other than cornea and hair transplant)
  • Participants with or who have a history of primary biliary cirrhosis, liver failure, hepatic carcinoma; decompensated liver cirrhosis with any the following diseases: ascites, jaundice, variceal hemorrhage, esophageal or gastric varices requiring treatment, hepatic encephalopathy, and idiopathic bacterial peritonitis; depression or schizophrenia requiring treatment, or suicidal attempt or suicidal ideation; epileptic seizures requiring treatment; angina, cardiac failure, myocardial infarction, or life-threatening arrhythmia; autoimmune disease (Hashimoto's disease, Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); hepatic carcinoma
  • Participants with a history of hypersensitivity to interferon preparations, biological products such as vaccine, or nucleoside analogs, and those with specific reaction to pegylated interferon alfa-2b in the prick test conducted before the initiation of treatment
  • Women who are pregnant or nursing as well as women for whom pregnancy cannot be ruled out by serum human chorionic gonadotropin (HCG) test conducted during the screening period. Male participants with partners who are pregnant.

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00687219     History of Changes
Other Study ID Numbers: P05116
First Posted: May 30, 2008    Key Record Dates
Results First Posted: December 2, 2011
Last Update Posted: April 7, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Keywords provided by Merck Sharp & Dohme Corp.:
hepatitis C

Additional relevant MeSH terms:
Hepatitis C
Liver Cirrhosis
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Pathologic Processes
Hepatitis, Chronic
Peginterferon alfa-2b
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs